<code id='D6F14B6897'></code><style id='D6F14B6897'></style>
    • <acronym id='D6F14B6897'></acronym>
      <center id='D6F14B6897'><center id='D6F14B6897'><tfoot id='D6F14B6897'></tfoot></center><abbr id='D6F14B6897'><dir id='D6F14B6897'><tfoot id='D6F14B6897'></tfoot><noframes id='D6F14B6897'>

    • <optgroup id='D6F14B6897'><strike id='D6F14B6897'><sup id='D6F14B6897'></sup></strike><code id='D6F14B6897'></code></optgroup>
        1. <b id='D6F14B6897'><label id='D6F14B6897'><select id='D6F14B6897'><dt id='D6F14B6897'><span id='D6F14B6897'></span></dt></select></label></b><u id='D6F14B6897'></u>
          <i id='D6F14B6897'><strike id='D6F14B6897'><tt id='D6F14B6897'><pre id='D6F14B6897'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:56
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In